루이소체 치매의 증상과 치료 = Clinical Features and Pharmacological Treatment of Dementia with Lewy Bodies

다국어 초록 (Multilingual Abstract)

Dementia with Lewy bodies (DLB) is the second most common causes of dementia. It can exhibit a variety of clinical symptoms including cognitive decline, cognitive fluctuation, visual hallucinations, parkinsonism, REM sleep behavior disorder, hypersensitivity to neuroleptics and autonomic dysfunctions. Despite more well-known criteria for DLB, there are often misdiagnosis and inappropriate treatment. It gives a lot of clinical burden to the clinician as well as to patients and families. When reducing the misdiagnosis, the burden of all will be reduced. The special concern and solicitation are needed in order not to miss the diagnosis when the cardinal features of DLB may not be volunteered by patients and the caregivers. To control the symptoms, clinicians must find and reduce drugs that can have the negative effects on DLB symptoms. There is limited evidence about specific interventions but available data suggest cholinesterase inhibitors improve the cognitive and behavioral symptoms and menmantine slightly improves the global impression.

참고문헌 (Reference)

1 김태희, "루이소체 치매의 진단과 치료" 대한노인정신의학회 16 (16): 75-81, 2012

2 Tiraboschi P, "What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?" 129 (129): 729-735, 2006

3 Harding AJ, "Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe" 125 (125): 391-403, 2002

4 Boeve BF, "Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort" 12 : 445-453, 2011

5 Boeve BF, "Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in a community-based sample" 9 : 475-480, 2013

6 Han S, "Validation of the Korean Lewy body composite risk score for discrimination of dementia with Lewy bodies in the Korean elderly" 15 : 1-1969, 2015

7 Karantzoulis S, "Update on dementia with lewy bodies" 2 : 196-204, 2013

8 Culo S, "Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial" 24 : 360-364, 2010

9 Vann Jones SA, "The prevalence and incidence of dementia with Lewy bodies: a systematic review of population and clinical studies" 44 : 673-683, 2014

10 Fernández-Arcos A, "The clinical phenotype of idiopathic rapid eye movement sleep behavior disorder at presentation: a study in 203 consecutive patients" 39 : 121-132, 2016

11 Ballard C, "The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies" 96 : 366-371, 1997

12 Walker MP, "The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia" 177 : 252-256, 2000

13 Chiba Y, "Retrospective survey of prodromal symptoms in dementia with Lewy bodies: comparison with Alzheimer’s disease" 33 : 273-281, 2012

14 Fahn S, "Recent Developments in Parkinson’s Disease" Macmillan Health Care Information 153-163, 1987

15 Iranzo A, "Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study" 5 : 572-577, 2006

16 Takahashi H, "Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series" 27 : 549-553, 2003

17 Postuma RB, "Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder" 72 : 1296-1300, 2009

18 Larsson V, "Quality of life and the effect of memantine in dementia with lewy bodies and Parkinson’s disease dementia" 32 : 227-234, 2011

19 Postuma RB, "Prodromal autonomic symptoms and signs in Parkinson’s disease and dementia with Lewy bodies" 28 : 597-604, 2013

20 Jhoo JH, "Prevalence of dementia and its subtypes in an elderly urban korean population:results from the Korean Longitudinal Study on Health And Aging (KLoSHA)" 26 : 270-276, 2008

21 Williams DR, "Predictors of falls and fractures in bradykinetic rigid syndromes: a retrospective study" 77 : 468-473, 2006

22 Stinton C, "Pharmacological management of Lewy body dementia: a systematic review and meta-analysis" 172 : 731-742, 2015

23 Ala TA, "Pentagon copying is more impaired in dementia with Lewy bodies than in Alzheimer’s disease" 70 : 483-488, 2001

24 Walker Z, "Olanzapine in dementia with Lewy bodies: a clinical study" 14 : 459-466, 1999

25 Imamura T, "Occipital glucose metabolism in dementia with lewy bodies with and without Parkinsonism: a study using positron emission tomography" 12 : 194-197, 2001

26 Oda H, "Neuropsychological profile of dementia with Lewy bodies" 9 : 85-90, 2009

27 Varanese S, "Modafinil and armodafinil improve attention and global mental status in Lewy bodies disorders: preliminary evidence" 28 : 1095-1097, 2013

28 Aarsland D, "Memantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial" 8 : 613-618, 2009

29 Wesnes KA, "Memantine improves attention and episodic memory in Parkinson’s disease dementia and dementia with Lewy bodies" 30 : 46-54, 2015

30 Emre M, "Memantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebocontrolled trial" 9 : 969-977, 2010

31 Mori E, "Longterm donepezil use for dementia with Lewy bodies: results from an open-label extension of Phase III trial" 7 : 5-, 2015

32 Baskys A, "Lewy body dementia: the litmus test for neuroleptic sensitivity and extrapyramidal symptoms" 65 (65): 16-22, 2004

33 Galvin JE, "Lewy body dementia: the caregiver experience of clinical care" 16 : 388-392, 2010

34 Galvin JE, "Lewy body dementia: caregiver burden and unmet needs" 24 : 177-181, 2010

35 Sethi K, "Levodopa unresponsive symptoms in Parkinson disease" 23 (23): S521-S533, 2008

36 Ferman TJ, "Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies" 77 : 875-882, 2011

37 Galvin JE, "Improving the clinical detection of lewy body dementia with the lewy body composite risk score" 1 : 316-324, 2015

38 McKeith I, "Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study" 356 : 2031-2036, 2000

39 Cummings JL, "Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies" 13 : 67-73, 2002

40 Edwards K, "Efficacy and safety of galantamine in patients with dementia with Lewy bodies: a 24-week open-label study" 23 : 401-405, 2007

41 Goldman JG, "Effects of dopaminergic medications on psychosis and motor function in dementia with Lewy bodies" 23 : 2248-2250, 2008

42 Mori E, "Donepezil-DLB Study Investigators. Donepezil for dementia with Lewy bodies: a randomized, placebocontrolled trial" 72 : 41-52, 2012

43 Ikeda M, "Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled, confirmatory phase III trial" 7 : 4-, 2015

44 Hanyu H, "Differences in clinical course between dementia with Lewy bodies and Alzheimer’s disease" 16 : 212-217, 2009

45 Neikrug AB, "Diagnostic tools for REM sleep behavior disorder" 16 : 415-429, 2012

46 American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" American Psychiatric Publishing 618-621, 2013

47 McKeith IG, "Diagnosis and management of dementia with Lewy bodies:third report of the DLB Consortium" 65 : 1863-1872, 2005

48 Barber R, "Dementia with Lewy bodies:diagnosis and management" 16 (16): S12-S18, 2001

49 Galasko DR, "Dementia with Lewy bodies" 13 : 69-86, 2007

50 McKeith I, "Dementia with Lewy bodies" 3 : 19-28, 2004

51 Ferman TJ, "DLB fluctuations: specific features that reliably differentiate DLB from AD and normal aging" 62 : 181-187, 2004

52 Boeve BF, "Current management of sleep disturbances in dementia" 2 : 169-177, 2002

53 McKeith IG, "Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop" 9 (9): 417-423, 2006

54 McKeith IG, "Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB) : report of the consortium on DLB international workshop" 47 : 1113-1124, 1996

55 Gnanalingham KK, "Clock-face drawing to differentiate Lewy body and Alzheimer type dementia syndromes" 347 : 696-697, 1996

56 Galvin JE, "Clinical phenotype of Parkinson disease dementia" 67 : 1605-1611, 2006

57 Ricci M, "Clinical findings, functional abilities and caregiver distress in the early stage of dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD)" 49 : e101-e104, 2009

58 Cagnin A, "Clinical and cognitive correlates of visual hallucinations in dementia with Lewy bodies" 84 : 505-510, 2013

59 Ballard CG, "Cholinesterase inhibitors reduce cortical Abeta in dementia with Lewy bodies" 68 : 1726-1729, 2007

60 Rolinski M, "Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson’s disease dementia and cognitive impairment in Parkinson’s disease" 3 : CD006504-, 2012

61 Borroni B, "Behavioral and psychological symptoms in dementia with Lewy-bodies (DLB): frequency and relationship with disease severity and motor impairment" 46 : 101-106, 2008

62 Kaufmann H, "Autonomic failure as the initial presentation of Parkinson disease and dementia with Lewy bodies" 63 : 1093-1095, 2004

63 Kurlan R, "Alzheimer’s Disease Cooperative Study Group. Quetiapine for agitation or psychosis in patients with dementia and parkinsonism" 68 : 1356-1363, 2007

64 Ferman TJ, "Abnormal daytime sleepiness in dementia with Lewy bodies compared to Alzheimer’s disease using the Multiple Sleep Latency Test" 6 : 76-, 2014

65 Zaccai J, "A systematic review of prevalence and incidence studies of dementia with Lewy bodies" 34 : 561-566, 2005

66 Whitworth HB, "A Caregiver’s Guide to Lewy Body Dementia" Demos Health 37-40, 2011